{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T17:53:07Z","timestamp":1790963587849,"version":"4.1.0"},"reference-count":67,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2018,6,15]],"date-time":"2018-06-15T00:00:00Z","timestamp":1529020800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Hematol Oncol"],"published-print":{"date-parts":[[2018,12]]},"DOI":"10.1186\/s13045-018-0621-5","type":"journal-article","created":{"date-parts":[[2018,6,15]],"date-time":"2018-06-15T07:35:35Z","timestamp":1529048135000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":72,"title":["NF-\u03baB signaling and its relevance to the treatment of mantle cell lymphoma"],"prefix":"10.1186","volume":"11","author":[{"given":"Swathi","family":"Balaji","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Makhdum","family":"Ahmed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth","family":"Lorence","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fangfang","family":"Yan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Krystle","family":"Nomie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,6,15]]},"reference":[{"key":"621_CR1","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1038\/nm.3435","volume":"20","author":"R Rahal","year":"2014","unstructured":"Rahal R, Frick M, Romero R, Korn JM, Kridel R, Chan FC, Meissner B, Bhang HE, Ruddy D, Kauffmann A, et al. Pharmacological and genomic profiling identifies NF-kappaB-targeted treatment strategies for mantle cell lymphoma. Nat Med. 2014;20:87\u201392.","journal-title":"Nat Med"},{"key":"621_CR2","doi-asserted-by":"publisher","first-page":"17723","DOI":"10.1073\/pnas.0509235102","volume":"102","author":"DH Broide","year":"2005","unstructured":"Broide DH, Lawrence T, Doherty T, Cho JY, Miller M, McElwain K, McElwain S, Karin M. Allergen-induced peribronchial fibrosis and mucus production mediated by IkappaB kinase beta-dependent genes in airway epithelium. Proc Natl Acad Sci U S A. 2005;102:17723\u20138.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"621_CR3","doi-asserted-by":"publisher","first-page":"1291","DOI":"10.1038\/nm1201-1291","volume":"7","author":"T Lawrence","year":"2001","unstructured":"Lawrence T, Gilroy DW, Colville-Nash PR, Willoughby DA. Possible new role for NF-kappaB in the resolution of inflammation. Nat Med. 2001;7:1291\u20137.","journal-title":"Nat Med"},{"key":"621_CR4","doi-asserted-by":"publisher","first-page":"839","DOI":"10.1006\/jmbi.1999.2912","volume":"290","author":"JA Taylor","year":"1999","unstructured":"Taylor JA, Bren GD, Pennington KN, Trushin SA, Asin S, Paya CV. Serine 32 and serine 36 of IkappaBalpha are directly phosphorylated by protein kinase CKII in vitro. J Mol Biol. 1999;290:839\u201350.","journal-title":"J Mol Biol"},{"key":"621_CR5","doi-asserted-by":"publisher","first-page":"8001","DOI":"10.1038\/sj.onc.1208075","volume":"23","author":"SB Gauld","year":"2004","unstructured":"Gauld SB, Cambier JC. Src-family kinases in B-cell development and signaling. Oncogene. 2004;23:8001\u20136.","journal-title":"Oncogene"},{"key":"621_CR6","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1016\/S1074-7613(00)80591-9","volume":"9","author":"C Fu","year":"1998","unstructured":"Fu C, Turck CW, Kurosaki T, Chan AC. BLNK: a central linker protein in B cell activation. Immunity. 1998;9:93\u2013103.","journal-title":"Immunity"},{"key":"621_CR7","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1002\/pro.321","volume":"19","author":"DJ Marcotte","year":"2010","unstructured":"Marcotte DJ, Liu YT, Arduini RM, Hession CA, Miatkowski K, Wildes CP, Cullen PF, Hong V, Hopkins BT, Mertsching E, et al. Structures of human Bruton\u2019s tyrosine kinase in active and inactive conformations suggest a mechanism of activation for TEC family kinases. Protein Sci. 2010;19:429\u201339.","journal-title":"Protein Sci"},{"key":"621_CR8","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1016\/j.jbior.2013.07.004","volume":"53","author":"T Rohacs","year":"2013","unstructured":"Rohacs T. Regulation of transient receptor potential channels by the phospholipase C pathway. Adv Biol Regul. 2013;53:341\u201355.","journal-title":"Adv Biol Regul"},{"key":"621_CR9","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1038\/cr.2010.182","volume":"21","author":"M Blonska","year":"2011","unstructured":"Blonska M, Lin X. NF-kappaB signaling pathways regulated by CARMA family of scaffold proteins. Cell Res. 2011;21:55\u201370.","journal-title":"Cell Res"},{"key":"621_CR10","doi-asserted-by":"publisher","first-page":"4681","DOI":"10.1182\/blood-2007-11-125278","volume":"111","author":"S Hewamana","year":"2008","unstructured":"Hewamana S, Alghazal S, Lin TT, Clement M, Jenkins C, Guzman ML, Jordan CT, Neelakantan S, Crooks PA, Burnett AK, et al. The NF-kappaB subunit Rel A is associated with in vitro survival and clinical disease progression in chronic lymphocytic leukemia and represents a promising therapeutic target. Blood. 2008;111:4681\u20139.","journal-title":"Blood"},{"key":"621_CR11","doi-asserted-by":"publisher","first-page":"1861","DOI":"10.1084\/jem.194.12.1861","volume":"194","author":"RE Davis","year":"2001","unstructured":"Davis RE, Brown KD, Siebenlist U, Staudt LM. Constitutive nuclear factor kappaB activity is required for survival of activated B cell-like diffuse large B cell lymphoma cells. J Exp Med. 2001;194:1861\u201374.","journal-title":"J Exp Med"},{"key":"621_CR12","doi-asserted-by":"publisher","first-page":"4269","DOI":"10.1038\/onc.2015.493","volume":"35","author":"MK Bognar","year":"2016","unstructured":"Bognar MK, Vincendeau M, Erdmann T, Seeholzer T, Grau M, Linnemann JR, Ruland J, Scheel CH, Lenz P, Ott G, et al. Oncogenic CARMA1 couples NF-kappaB and beta-catenin signaling in diffuse large B-cell lymphomas. Oncogene. 2016;35:4269\u201381.","journal-title":"Oncogene"},{"key":"621_CR13","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1111\/ejh.12427","volume":"94","author":"V Seda","year":"2015","unstructured":"Seda V, Mraz M. B-cell receptor signalling and its crosstalk with other pathways in normal and malignant cells. Eur J Haematol. 2015;94:193\u2013205.","journal-title":"Eur J Haematol"},{"key":"621_CR14","doi-asserted-by":"publisher","first-page":"13075","DOI":"10.1073\/pnas.1004594107","volume":"107","author":"LA Honigberg","year":"2010","unstructured":"Honigberg LA, Smith AM, Sirisawad M, Verner E, Loury D, Chang B, Li S, Pan Z, Thamm DH, Miller RA, Buggy JJ. The Bruton tyrosine kinase inhibitor PCI-32765 blocks B-cell activation and is efficacious in models of autoimmune disease and B-cell malignancy. Proc Natl Acad Sci U S A. 2010;107:13075\u201380.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"621_CR15","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1186\/s13045-016-0250-9","volume":"9","author":"J Wu","year":"2016","unstructured":"Wu J, Zhang M, Liu D. Acalabrutinib (ACP-196): a selective second-generation BTK inhibitor. J Hematol Oncol. 2016;9:21.","journal-title":"J Hematol Oncol"},{"key":"621_CR16","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1186\/s13045-016-0313-y","volume":"9","author":"J Wu","year":"2016","unstructured":"Wu J, Liu C, Tsui ST, Liu D. Second-generation inhibitors of Bruton tyrosine kinase. J Hematol Oncol. 2016;9:80.","journal-title":"J Hematol Oncol"},{"key":"621_CR17","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1182\/blood-2015-11-681460","volume":"128","author":"NS Saba","year":"2016","unstructured":"Saba NS, Liu D, Herman SE, Underbayev C, Tian X, Behrend D, Weniger MA, Skarzynski M, Gyamfi J, Fontan L, et al. Pathogenic role of B-cell receptor signaling and canonical NF-kappaB activation in mantle cell lymphoma. Blood. 2016;128:82\u201392.","journal-title":"Blood"},{"key":"621_CR18","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1038\/nature08638","volume":"463","author":"RE Davis","year":"2010","unstructured":"Davis RE, Ngo VN, Lenz G, Tolar P, Young RM, Romesser PB, Kohlhammer H, Lamy L, Zhao H, Yang Y, et al. Chronic active B-cell-receptor signalling in diffuse large B-cell lymphoma. Nature. 2010;463:88\u201392.","journal-title":"Nature"},{"key":"621_CR19","doi-asserted-by":"publisher","first-page":"1430","DOI":"10.1056\/NEJMoa1501548","volume":"372","author":"SP Treon","year":"2015","unstructured":"Treon SP, Tripsas CK, Meid K, Warren D, Varma G, Green R, Argyropoulos KV, Yang G, Cao Y, Xu L, et al. Ibrutinib in previously treated Waldenstrom\u2019s macroglobulinemia. N Engl J Med. 2015;372:1430\u201340.","journal-title":"N Engl J Med"},{"key":"621_CR20","doi-asserted-by":"publisher","first-page":"782","DOI":"10.1002\/cncr.27792","volume":"119","author":"L Wang","year":"2013","unstructured":"Wang L, Zhao Y, Qian J, Sun L, Lu Y, Li H, Li Y, Yang J, Cai Z, Yi Q. Toll-like receptor-4 signaling in mantle cell lymphoma: effects on tumor growth and immune evasion. Cancer. 2013;119:782\u201391.","journal-title":"Cancer"},{"key":"621_CR21","doi-asserted-by":"publisher","first-page":"667","DOI":"10.1038\/ni809","volume":"3","author":"Y Nagai","year":"2002","unstructured":"Nagai Y, Akashi S, Nagafuku M, Ogata M, Iwakura Y, Akira S, Kitamura T, Kosugi A, Kimoto M, Miyake K. Essential role of MD-2 in LPS responsiveness and TLR4 distribution. Nat Immunol. 2002;3:667\u201372.","journal-title":"Nat Immunol"},{"key":"621_CR22","doi-asserted-by":"publisher","first-page":"24192","DOI":"10.1074\/jbc.M109.023044","volume":"284","author":"B Verstak","year":"2009","unstructured":"Verstak B, Nagpal K, Bottomley SP, Golenbock DT, Hertzog PJ, Mansell A. MyD88 adapter-like (Mal)\/TIRAP interaction with TRAF6 is critical for TLR2- and TLR4-mediated NF-kappaB proinflammatory responses. J Biol Chem. 2009;284:24192\u2013203.","journal-title":"J Biol Chem"},{"key":"621_CR23","doi-asserted-by":"publisher","first-page":"37436","DOI":"10.1074\/jbc.M400241200","volume":"279","author":"Y Liu","year":"2004","unstructured":"Liu Y, Dong W, Chen L, Xiang R, Xiao H, De G, Wang Z, Qi Y. BCL10 mediates lipopolysaccharide\/toll-like receptor-4 signaling through interaction with Pellino2. J Biol Chem. 2004;279:37436\u201344.","journal-title":"J Biol Chem"},{"key":"621_CR24","doi-asserted-by":"publisher","first-page":"962","DOI":"10.1038\/ni1367","volume":"7","author":"M Yamamoto","year":"2006","unstructured":"Yamamoto M, Okamoto T, Takeda K, Sato S, Sanjo H, Uematsu S, Saitoh T, Yamamoto N, Sakurai H, Ishii KJ, et al. Key function for the Ubc13 E2 ubiquitin-conjugating enzyme in immune receptor signaling. Nat Immunol. 2006;7:962\u201370.","journal-title":"Nat Immunol"},{"key":"621_CR25","doi-asserted-by":"publisher","first-page":"e0153823","DOI":"10.1371\/journal.pone.0153823","volume":"11","author":"K Mastorci","year":"2016","unstructured":"Mastorci K, Muraro E, Pasini E, Furlan C, Sigalotti L, Cinco M, Dolcetti R, Fratta E. Toll-like receptor 1\/2 and 5 ligands enhance the expression of cyclin D1 and D3 and induce proliferation in mantle cell lymphoma. PLoS One. 2016;11:e0153823.","journal-title":"PLoS One"},{"key":"621_CR26","doi-asserted-by":"publisher","first-page":"1490","DOI":"10.1158\/1078-0432.CCR-04-1890","volume":"11","author":"B Jahrsdorfer","year":"2005","unstructured":"Jahrsdorfer B, Muhlenhoff L, Blackwell SE, Wagner M, Poeck H, Hartmann E, Jox R, Giese T, Emmerich B, Endres S, et al. B-cell lymphomas differ in their responsiveness to CpG oligodeoxynucleotides. Clin Cancer Res. 2005;11:1490\u20139.","journal-title":"Clin Cancer Res"},{"key":"621_CR27","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1002\/hon.2251","volume":"35","author":"A Akhter","year":"2017","unstructured":"Akhter A, Street L, Ghosh S, Burns BF, Elyamany G, Shabani-Rad MT, Stewart DA, Mansoor A. Concomitant high expression of toll-like receptor (TLR) and B-cell receptor (BCR) signalling molecules has clinical implications in mantle cell lymphoma. Hematol Oncol. 2017;35:79\u201386.","journal-title":"Hematol Oncol"},{"key":"621_CR28","doi-asserted-by":"publisher","first-page":"412","DOI":"10.1038\/7410","volume":"5","author":"CY Wang","year":"1999","unstructured":"Wang CY, Cusack JC Jr, Liu R, Baldwin AS Jr. Control of inducible chemoresistance: enhanced anti-tumor therapy through increased apoptosis by inhibition of NF-kappaB. Nat Med. 1999;5:412\u20137.","journal-title":"Nat Med"},{"key":"621_CR29","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1016\/S1074-7613(00)80252-6","volume":"4","author":"H Hsu","year":"1996","unstructured":"Hsu H, Huang J, Shu HB, Baichwal V, Goeddel DV. TNF-dependent recruitment of the protein kinase RIP to the TNF receptor-1 signaling complex. Immunity. 1996;4:387\u201396.","journal-title":"Immunity"},{"key":"621_CR30","doi-asserted-by":"publisher","first-page":"10838","DOI":"10.1074\/jbc.275.15.10838","volume":"275","author":"WH Hu","year":"2000","unstructured":"Hu WH, Johnson H, Shu HB. Activation of NF-kappaB by FADD, Casper, and caspase-8. J Biol Chem. 2000;275:10838\u201344.","journal-title":"J Biol Chem"},{"key":"621_CR31","doi-asserted-by":"publisher","first-page":"8377","DOI":"10.1128\/MCB.23.22.8377-8385.2003","volume":"23","author":"TH Lee","year":"2003","unstructured":"Lee TH, Huang Q, Oikemus S, Shank J, Ventura JJ, Cusson N, Vaillancourt RR, Su B, Davis RJ, Kelliher MA. The death domain kinase RIP1 is essential for tumor necrosis factor alpha signaling to p38 mitogen-activated protein kinase. Mol Cell Biol. 2003;23:8377\u201385.","journal-title":"Mol Cell Biol"},{"key":"621_CR32","doi-asserted-by":"publisher","first-page":"3044","DOI":"10.1093\/emboj\/18.11.3044","volume":"18","author":"L Sanz","year":"1999","unstructured":"Sanz L, Sanchez P, Lallena MJ, Diaz-Meco MT, Moscat J. The interaction of p62 with RIP links the atypical PKCs to NF-kappaB activation. EMBO J. 1999;18:3044\u201353.","journal-title":"EMBO J"},{"key":"621_CR33","doi-asserted-by":"publisher","first-page":"e0174112","DOI":"10.1371\/journal.pone.0174112","volume":"12","author":"Y Zhang","year":"2017","unstructured":"Zhang Y, Zhang R, Ding X, Peng B, Wang N, Ma F, Peng Y, Wang Q, Chang J. FNC efficiently inhibits mantle cell lymphoma growth. PLoS One. 2017;12:e0174112.","journal-title":"PLoS One"},{"key":"621_CR34","doi-asserted-by":"publisher","first-page":"22111","DOI":"10.1074\/jbc.C200151200","volume":"277","author":"A Fong","year":"2002","unstructured":"Fong A, Sun SC. Genetic evidence for the essential role of beta-transducin repeat-containing protein in the inducible processing of NF-kappa B2\/p100. J Biol Chem. 2002;277:22111\u20134.","journal-title":"J Biol Chem"},{"key":"621_CR35","doi-asserted-by":"publisher","first-page":"4554","DOI":"10.18632\/oncotarget.2128","volume":"5","author":"YN Demchenko","year":"2014","unstructured":"Demchenko YN, Brents LA, Li Z, Bergsagel LP, McGee LR, Kuehl MW. Novel inhibitors are cytotoxic for myeloma cells with NFkB inducing kinase-dependent activation of NFkB. Oncotarget. 2014;5:4554\u201366.","journal-title":"Oncotarget"},{"key":"621_CR36","doi-asserted-by":"publisher","first-page":"26243","DOI":"10.1074\/jbc.M403286200","volume":"279","author":"G Liao","year":"2004","unstructured":"Liao G, Zhang M, Harhaj EW, Sun SC. Regulation of the NF-kappaB-inducing kinase by tumor necrosis factor receptor-associated factor 3-induced degradation. J Biol Chem. 2004;279:26243\u201350.","journal-title":"J Biol Chem"},{"key":"621_CR37","doi-asserted-by":"crossref","first-page":"3047","DOI":"10.1182\/blood.V124.21.3047.3047","volume":"124","author":"P Martin","year":"2014","unstructured":"Martin P, Maddocks KJ, Noto K, Christian B, Furman RR, Andritsos LA, Flynn JM, Jones JA, Ruan J, Chen-Kiang S, et al. Poor overall survival of patients with ibrutinib-resistant mantle cell lymphoma. Blood. 2014;124:3047.","journal-title":"Blood"},{"key":"621_CR38","doi-asserted-by":"publisher","first-page":"1298","DOI":"10.1158\/1538-7445.AM2016-1298","volume":"76","author":"Z Sun","year":"2016","unstructured":"Sun Z, Luo L. Abstract 1298: CD40L-CD40 signaling on B-cell lymphoma response to BTK inhibitors. Cancer Res. 2016;76:1298.","journal-title":"Cancer Res"},{"key":"621_CR39","doi-asserted-by":"publisher","first-page":"958","DOI":"10.1038\/ni842","volume":"3","author":"E Claudio","year":"2002","unstructured":"Claudio E, Brown K, Park S, Wang H, Siebenlist U. BAFF-induced NEMO-independent processing of NF-kappa B2 in maturing B cells. Nat Immunol. 2002;3:958\u201365.","journal-title":"Nat Immunol"},{"key":"621_CR40","doi-asserted-by":"publisher","first-page":"10018","DOI":"10.1074\/jbc.M413634200","volume":"280","author":"MD Morrison","year":"2005","unstructured":"Morrison MD, Reiley W, Zhang M, Sun SC. An atypical tumor necrosis factor (TNF) receptor-associated factor-binding motif of B cell-activating factor belonging to the TNF family (BAFF) receptor mediates induction of the noncanonical NF-kappaB signaling pathway. J Biol Chem. 2005;280:10018\u201324.","journal-title":"J Biol Chem"},{"key":"621_CR41","doi-asserted-by":"crossref","unstructured":"Han SS, Yun H, Son DJ, Tompkins VS, Peng L, Chung ST, Kim JS, Park ES, Janz S: NF-kappaB\/STAT3\/PI3K signaling crosstalk in iMyc E mu B lymphoma. Mol Cancer 2010, 9:97.","DOI":"10.1186\/1476-4598-9-97"},{"key":"621_CR42","doi-asserted-by":"publisher","first-page":"2863","DOI":"10.1002\/ijc.24748","volume":"125","author":"D Bai","year":"2009","unstructured":"Bai D, Ueno L, Vogt PK. Akt-mediated regulation of NFkappaB and the essentialness of NFkappaB for the oncogenicity of PI3K and Akt. Int J Cancer. 2009;125:2863\u201370.","journal-title":"Int J Cancer"},{"key":"621_CR43","doi-asserted-by":"publisher","first-page":"516","DOI":"10.1111\/j.1365-2141.2005.05630.x","volume":"130","author":"EG Rizzatti","year":"2005","unstructured":"Rizzatti EG, Falcao RP, Panepucci RA, Proto-Siqueira R, Anselmo-Lima WT, Okamoto OK, Zago MA. Gene expression profiling of mantle cell lymphoma cells reveals aberrant expression of genes from the PI3K-AKT, WNT and TGFbeta signalling pathways. Br J Haematol. 2005;130:516\u201326.","journal-title":"Br J Haematol"},{"key":"621_CR44","doi-asserted-by":"publisher","first-page":"3406","DOI":"10.1182\/blood-2013-11-538546","volume":"123","author":"IW Flinn","year":"2014","unstructured":"Flinn IW, Kahl BS, Leonard JP, Furman RR, Brown JR, Byrd JC, Wagner-Johnston ND, Coutre SE, Benson DM, Peterman S, et al. Idelalisib, a selective inhibitor of phosphatidylinositol 3-kinase-delta, as therapy for previously treated indolent non-Hodgkin lymphoma. Blood. 2014;123:3406\u201313.","journal-title":"Blood"},{"key":"621_CR45","doi-asserted-by":"crossref","first-page":"3016","DOI":"10.1182\/blood.V128.22.3016.3016","volume":"128","author":"J Wang","year":"2016","unstructured":"Wang J, Zhang V, Bell T, Liu Y, Guo H, Zhang L. The effects of PI3K-\u03b4\/\u03b3 inhibitor, duvelisib, in mantle cell lymphoma in vitro and in patient-derived xenograft studies. Blood. 2016;128:3016.","journal-title":"Blood"},{"key":"621_CR46","doi-asserted-by":"publisher","first-page":"350","DOI":"10.1097\/MOH.0000000000000057","volume":"21","author":"N Saba","year":"2014","unstructured":"Saba N, Wiestner A. Do mantle cell lymphomas have an \u2018Achilles heel\u2019? Curr Opin Hematol. 2014;21:350\u20137.","journal-title":"Curr Opin Hematol"},{"key":"621_CR47","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1016\/j.ccr.2013.12.011","volume":"25","author":"D Colomer","year":"2014","unstructured":"Colomer D, Campo E. Unlocking new therapeutic targets and resistance mechanisms in mantle cell lymphoma. Cancer Cell. 2014;25:7\u20139.","journal-title":"Cancer Cell"},{"key":"621_CR48","doi-asserted-by":"publisher","first-page":"394","DOI":"10.1111\/bjh.13973","volume":"173","author":"H Rauert-Wunderlich","year":"2016","unstructured":"Rauert-Wunderlich H, Rudelius M, Ott G, Rosenwald A. Targeting protein kinase C in mantle cell lymphoma. Br J Haematol. 2016;173:394\u2013403.","journal-title":"Br J Haematol"},{"key":"621_CR49","doi-asserted-by":"publisher","first-page":"E7230","DOI":"10.1073\/pnas.1507459112","volume":"112","author":"N Knies","year":"2015","unstructured":"Knies N, Alankus B, Weilemann A, Tzankov A, Brunner K, Ruff T, Kremer M, Keller UB, Lenz G, Ruland J. Lymphomagenic CARD11\/BCL10\/MALT1 signaling drives malignant B-cell proliferation via cooperative NF-kappaB and JNK activation. Proc Natl Acad Sci U S A. 2015;112:E7230\u20138.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"621_CR50","doi-asserted-by":"publisher","first-page":"6410","DOI":"10.1158\/0008-5472.CAN-16-0595","volume":"76","author":"H Zhang","year":"2016","unstructured":"Zhang H, Chen Z, Miranda RN, Medeiros LJ, McCarty N. TG2 and NF-kappaB signaling coordinates the survival of mantle cell lymphoma cells via IL6-mediated autophagy. Cancer Res. 2016;76:6410\u201323.","journal-title":"Cancer Res"},{"key":"621_CR51","doi-asserted-by":"publisher","first-page":"2568","DOI":"10.1182\/blood-2011-09-377598","volume":"119","author":"HJ Jung","year":"2012","unstructured":"Jung HJ, Chen Z, Wang M, Fayad L, Romaguera J, Kwak LW, McCarty N. Calcium blockers decrease the bortezomib resistance in mantle cell lymphoma via manipulation of tissue transglutaminase activities. Blood. 2012;119:2568\u201378.","journal-title":"Blood"},{"key":"621_CR52","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1002\/hon.2437_39","volume":"35","author":"MS Davids","year":"2017","unstructured":"Davids MS, Kim HT, Nicotra A, Savell A, Francoeur K, Hellman JM, Miskin H, Sportelli P, Bashey A, Stampleman L, et al. Updated results of a multicenter phase I\/IB study of TGR-1202 in combination with ibrutinib in patients with relapsed or refractory MCL or CLL. Hematol Oncol. 2017;35:54\u20135.","journal-title":"Hematol Oncol"},{"key":"621_CR53","doi-asserted-by":"publisher","first-page":"e447","DOI":"10.3324\/haematol.2017.168930","volume":"102","author":"A Vidal-Crespo","year":"2017","unstructured":"Vidal-Crespo A, Rodriguez V, Matas-Cespedes A, Lee E, Rivas-Delgado A, Gin\u00e9 E, Navarro A, Be\u00e0 S, Campo E, L\u00f3pez-Guillermo A, et al. The Bruton tyrosine kinase inhibitor CC-292 shows activity in mantle cell lymphoma and synergizes with lenalidomide and NIK inhibitors depending on nuclear factor-\u03baB mutational status. Haematologica. 2017;102:e447.","journal-title":"Haematologica"},{"key":"621_CR54","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1056\/NEJMoa1306220","volume":"369","author":"ML Wang","year":"2013","unstructured":"Wang ML, Rule S, Martin P, Goy A, Auer R, Kahl BS, Jurczak W, Advani RH, Romaguera JE, Williams ME, et al. Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma. N Engl J Med. 2013;369:507\u201316.","journal-title":"N Engl J Med"},{"key":"621_CR55","doi-asserted-by":"publisher","first-page":"659","DOI":"10.1016\/S0140-6736(17)33108-2","volume":"391","author":"M Wang","year":"2018","unstructured":"Wang M, Rule S, Zinzani PL, Goy A, Casasnovas O, Smith SD, Damaj G, Doorduijn J, Lamy T, Morschhauser F, et al. Acalabrutinib in relapsed or refractory mantle cell lymphoma (ACE-LY-004): a single-arm, multicentre, phase 2 trial. Lancet. 2018;391:659\u201367.","journal-title":"Lancet"},{"key":"621_CR56","doi-asserted-by":"publisher","first-page":"4867","DOI":"10.1200\/JCO.2006.07.9665","volume":"24","author":"RI Fisher","year":"2006","unstructured":"Fisher RI, Bernstein SH, Kahl BS, Djulbegovic B, Robertson MJ, de Vos S, Epner E, Krishnan A, Leonard JP, Lonial S, et al. Multicenter phase II study of bortezomib in patients with relapsed or refractory mantle cell lymphoma. J Clin Oncol. 2006;24:4867\u201374.","journal-title":"J Clin Oncol"},{"key":"621_CR57","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1158\/0008-5472.264.65.1","volume":"65","author":"AR Jazirehi","year":"2005","unstructured":"Jazirehi AR, Huerta-Yepez S, Cheng G, Bonavida B. Rituximab (chimeric anti-CD20 monoclonal antibody) inhibits the constitutive nuclear factor-{kappa}B signaling pathway in non-Hodgkin\u2019s lymphoma B-cell lines: role in sensitization to chemotherapeutic drug-induced apoptosis. Cancer Res. 2005;65:264\u201376.","journal-title":"Cancer Res"},{"key":"621_CR58","doi-asserted-by":"publisher","first-page":"3398","DOI":"10.1182\/blood-2013-11-537555","volume":"123","author":"BS Kahl","year":"2014","unstructured":"Kahl BS, Spurgeon SE, Furman RR, Flinn IW, Coutre SE, Brown JR, Benson DM, Byrd JC, Peterman S, Cho Y, et al. A phase 1 study of the PI3Kdelta inhibitor idelalisib in patients with relapsed\/refractory mantle cell lymphoma (MCL). Blood. 2014;123:3398\u2013405.","journal-title":"Blood"},{"key":"621_CR59","doi-asserted-by":"publisher","first-page":"866","DOI":"10.1016\/j.bbrc.2006.09.097","volume":"350","author":"HS Youn","year":"2006","unstructured":"Youn HS, Lee JY, Saitoh SI, Miyake K, Hwang DH. Auranofin, as an anti-rheumatic gold compound, suppresses LPS-induced homodimerization of TLR4. Biochem Biophys Res Commun. 2006;350:866\u201371.","journal-title":"Biochem Biophys Res Commun"},{"key":"621_CR60","doi-asserted-by":"publisher","first-page":"792","DOI":"10.1158\/1538-7445.AM2015-792","volume":"75","author":"S Reddy","year":"2015","unstructured":"Reddy S, Damle NK, Venkatesan AM, Thompson SK, Rao N, Smith RA, Gupta S. Abstract 792: ASN002: a novel dual SYK\/JAK inhibitor with strong antitumor activity. Cancer Res. 2015;75:792.","journal-title":"Cancer Res"},{"key":"621_CR61","doi-asserted-by":"crossref","first-page":"4183","DOI":"10.1182\/blood.V128.22.4183.4183","volume":"128","author":"JN Boyle","year":"2016","unstructured":"Boyle JN, Kim CR, Guo H, Bell T, Huang S, Li CJ, Liu Y, Zhang H, Wang J, Zhang V, et al. CUDC-907: an oral HDAC\/PI3K dual inhibitor with strong preclinical efficacy in MCL model. Blood. 2016;128:4183.","journal-title":"Blood"},{"key":"621_CR62","doi-asserted-by":"crossref","first-page":"13085","DOI":"10.18632\/oncotarget.14393","volume":"8","author":"T Aoki","year":"2017","unstructured":"Aoki T, Shimada K, Sakamoto A, Sugimoto K, Morishita T, Kojima Y, Shimada S, Kato S, Iriyama C, Kuno S, et al. Emetine elicits apoptosis of intractable B-cell lymphoma cells with MYC rearrangement through inhibition of glycolytic metabolism. Oncotarget. 2017;8:13085\u201398.","journal-title":"Oncotarget"},{"key":"621_CR63","doi-asserted-by":"publisher","first-page":"3669","DOI":"10.1182\/blood-2003-11-3775","volume":"103","author":"BD Smith","year":"2004","unstructured":"Smith BD, Levis M, Beran M, Giles F, Kantarjian H, Berg K, Murphy KM, Dauses T, Allebach J, Small D. Single-agent CEP-701, a novel FLT3 inhibitor, shows biologic and clinical activity in patients with relapsed or refractory acute myeloid leukemia. Blood. 2004;103:3669\u201376.","journal-title":"Blood"},{"key":"621_CR64","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1586\/ecp.12.2","volume":"5","author":"M Ham","year":"2012","unstructured":"Ham M, Moss AC. Mesalamine in the treatment and maintenance of remission of ulcerative colitis. Expert Rev Clin Pharmacol. 2012;5:113\u201323.","journal-title":"Expert Rev Clin Pharmacol"},{"key":"621_CR65","doi-asserted-by":"publisher","first-page":"1476","DOI":"10.1038\/leu.2010.117","volume":"24","author":"Z Zak","year":"2010","unstructured":"Zak Z, Gelebart P, Lai R. Fenofibrate induces effective apoptosis in mantle cell lymphoma by inhibiting the TNFalpha\/NF-kappaB signaling axis. Leukemia. 2010;24:1476\u201386.","journal-title":"Leukemia"},{"key":"621_CR66","doi-asserted-by":"publisher","first-page":"2269","DOI":"10.1182\/blood-2004-03-1091","volume":"104","author":"H Kaufmann","year":"2004","unstructured":"Kaufmann H, Raderer M, Wohrer S, Puspok A, Bankier A, Zielinski C, Chott A, Drach J. Antitumor activity of rituximab plus thalidomide in patients with relapsed\/refractory mantle cell lymphoma. Blood. 2004;104:2269\u201371.","journal-title":"Blood"},{"key":"621_CR67","doi-asserted-by":"publisher","first-page":"1835","DOI":"10.1056\/NEJMoa1505237","volume":"373","author":"J Ruan","year":"2015","unstructured":"Ruan J, Martin P, Shah B, Schuster SJ, Smith SM, Furman RR, Christos P, Rodriguez A, Svoboda J, Lewis J, et al. Lenalidomide plus rituximab as initial treatment for mantle-cell lymphoma. N Engl J Med. 2015;373:1835\u201344.","journal-title":"N Engl J Med"}],"container-title":["Journal of Hematology & Oncology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13045-018-0621-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s13045-018-0621-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13045-018-0621-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,8,25]],"date-time":"2022-08-25T19:55:28Z","timestamp":1661457328000},"score":1,"resource":{"primary":{"URL":"https:\/\/jhoonline.biomedcentral.com\/articles\/10.1186\/s13045-018-0621-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,6,15]]},"references-count":67,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2018,12]]}},"alternative-id":["621"],"URL":"https:\/\/doi.org\/10.1186\/s13045-018-0621-5","relation":{},"ISSN":["1756-8722"],"issn-type":[{"value":"1756-8722","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,6,15]]},"assertion":[{"value":"29 January 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 May 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 June 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Not applicable","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"The authors declare that they have no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Publisher\u2019s Note"}}],"article-number":"83"}}